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Overactive bladder syndrome (OAB) was first de-
scribed in 1996 and is defined by the presence of uri-
nary urgency, with or without urge incontinence, usual-
ly accompanied by an increase in urinary frequency and 
nocturia in the absence of urinary tract infections (UTI) 
or other diseases [1-3].
Symptoms of OAB are also common to interstitial 
cystitis/painful bladder syndrome (IC/PBS) [4]. Howev-
er, we can distinguish these diseases by the presence 
of urinary incontinence in patients with OAB and pelvic 
pain in patients with IC/PBS [4, 5]. Furthermore, OAB 
often occurs concomitantly with pelvic organ prolapse 
(POP) with a significant impairment of the quality of life 
of women affected [6-9]. It has been underlined that 
OAB symptoms improve after treatment of POP [10-17].
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Abstract
Overactive bladder syndrome (OAB) is defined by the presence of urinary urgency, with or without urge 
incontinence, usually accompanied by an increase in urinary frequency and nocturia in the absence of urinary 
tract infections (UTI) or other diseases. The overall prevalence of OAB symptoms in the female population is 
reported to be 16.6% and increases with advancing age and menopause. The aetiology of OAB is not fully 
understood and is likely to affect a heterogeneous population of patients due to changes to their central and 
peripheral nervous systems. Although OAB is frequently associated with female sexual dysfunction (FSD), its 
real impact on sexual function in women has been evaluated only in a few studies. The first line of treatment 
for OAB includes behavioural modification and physical therapy, either as monotherapies or in combination. 
Many patients who have not had success in managing their symptoms with more conservative therapies may 
decide to resort to third-line treatments for refractory OAB. These treatments include neuromodulation thera-
pies, particularly transvaginal electrical stimulation (TES) and sacral neuromodulation (SN). The aim of this short 
commentary is to provide an overview of the effectiveness of these treatments and of their impact on quality 
of life, body image, sexual function, and emotional well-being. 
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In addition, there seems to be a significant associ-
ation between anterior and/or fundal leiomyoma and 
OAB. For this reason, the presence of uterine leiomyo-
ma should be taken into account in women affected by 
overactive bladder [18-21].
Bladder dysfunctions are also common after radi-
cal hysterectomy and radiotherapy for the treatment of 
gynaecological cancer [22-27]. Therefore, urinary symp-
toms should always be evaluated in cancer patients 
[27, 28].
Recently, a  possible relationship between postpar-
tum depression and symptoms of overactive bladder 
in postpartum women was hypothesised. Postpartum 
depression is a common complication of childbirth, and 
a  number of studies have underlined a  link between 
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this condition and urinary symptoms [29-31]. Although 
it is difficult to establish the cause and/or effect rela-
tionship between the two conditions, the simultaneous 
presence of depression and urinary incontinence is 
associated with a worsening quality of life in affected 
women [30, 31]. 
The aetiology of OAB is not fully understood and is 
likely to affect a heterogeneous population of patients 
due to changes to their central and peripheral nervous 
systems [32]. The overall prevalence of OAB symptoms 
in the female population is reported to be 16.6% and 
increases with advancing age and menopause [33-36]. 
In this regard, the signs of menopause may be closely 
associated with a higher prevalence of OAB and more 
severe symptoms [37, 38]. Furthermore, many women 
in menopausal age who suffer from this condition wait 
for years before undergoing treatment because of the 
lack of knowledge and shame associated with these 
symptoms [39].
The pathophysiology of OAB is complex and incom-
pletely understood. The detrusor muscle is activated 
by the parasympathetic nervous system through the 
nerves originating at S2, S3, and S4 level [40]. The im-
pulse is transmitted through acetylcholine (ACh), which 
acts a mediator on the muscarinic receptors, namely its 
action on the M3 subtype is the main cause for the con-
traction of the muscle tissue of the bladder. However, 
recent research has shown the role of the urothelium 
and the suburothelium in the perception of sensorial 
stimuli, and numerous pathological variations of ex-
pressed receptors have been reported in sufferers with 
OAB [41].
Several studies have underlined that OAB drastical-
ly reduces quality of life because of its negative influ-
ence on many aspects of patients’ lives, including so-
cial, physical, and psychological well-being, and work 
productivity [42-45]. Moreover, both sexual desire and 
the capacity to reach an orgasm through penetration 
are impaired in female patients with OAB, thus affect-
ing their sexual health [46, 47]. Not surprisingly, many 
papers have reported that urinary symptoms can cause 
a huge psychological burden, likely to affect mental and 
sexual health through the production of negative emo-
tions [47-52]. Although OAB is frequently associated 
with female sexual dysfunction (FSD), its real impact 
on sexual function in women has been evaluated only 
in a few studies [42, 45-56]. In this regard, one of the 
most frequently used questionnaires in the literature 
to evaluate sexual dysfunctions related to different dis-
eases is the Female Sexual Function Index (FSFI) [57-
60]. Data obtained through the use of this instrument 
underline that much more women with OAB report sex-
ual dysfunction than the general, healthy female pop-
ulation without urinary symptoms [54, 55]. Moreover, 
in postmenopausal women, there is an association be-
tween severity of OAB symptoms and worsening sexu-
al function, mainly in the domains of arousal, lubrica-
tion, orgasm, and pain [47, 61-64]. In this regard, the 
studies by Zhu et al. [38] and Hakimi et al. [39] confirm 
that women in menopausal age with OAB report lower 
scores in all sub-domains of sexual function than wom-
en who do not suffer from OAB. Furthermore, OAB is as-
sociated with a reduced frequency of sexual intercourse 
during menopause [39].
Nevertheless, further studies on this topic are need-
ed in order to better understand the effects of OAB 
symptoms on sexual function and to improve sexual 
health in the affected women. 
The first line of treatment for OAB includes be-
havioural modification and physical therapy, either as 
monotherapies or in combination [65, 66]. First-line 
medical therapies are usually associated with a second- 
line of treatment of anticholinergics and β-3 agonists, 
before potentially considering invasive surgical treat-
ments such as urinary diversion [66]. However, these 
medications are often characterised by lack of effica-
cy, poor compliance, low patient satisfaction, and side 
effects [67-69]. For these reasons, many patients who 
have not had success in managing their symptoms 
with more conservative therapies may decide to resort 
to third-line treatments for refractory OAB [70]. These 
treatments include neuromodulation therapies, par-
ticularly transvaginal electrical stimulation (TES) and 
sacral neuromodulation (SN) [67, 69, 70]. 
TES is a  conservative treatment option, described 
more than 40 years ago, which allows the use of a sur-
gical approach later, if necessary [71, 72]. With TES, af-
ter attaching a sensor with electrodes in the vagina, the 
muscles of the pelvic floor are activated through a pain-
less electric current [73, 74]. Different frequencies result 
in different outcomes. Pelvic floor muscles (PFMs) can 
be activated with frequencies between 35 and 40 Hz, 
while at 5-10 Hz the effects spread also to the detru-
sor muscle. Based on results from randomised clinical 
trials, a  frequency of 50 Hz has been recommended 
for patients with Stress Urinary Incontinence (SUI) and 
a frequency of 10-20 Hz for urge urinary incontinence 
(UUI). The device is applied transvaginally, and treat-
ment sessions are run daily for a course of about 4-12 
weeks and last about 15 to 30 minutes at the highest 
intensity that the patient is able to endure. Cure and 
clinical improvement rates vary between 60% and 80%, 
and no harmful side effects have ever occurred [75-77]. 
Being a  conservative treatment, TES is often recom-
mended in cases of mild or moderate cases of UUI; in 
addition to this, new research has been suggested us-
ing TES also for treating FSD, but its efficacy still needs 
to be shown [78-80]. In this regard, Giuseppe et al. [81] 
evaluated 37 women with UUI (23 of them also suffer-
ing from FSDs) using a  voiding diary and FSFI before 
and after three months of TES. The results of this study 
showed a significant improvement of sexual function in 
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the 23 women with UUI and FSD after three months of 
TES [81]. Moreover, several studies underline the effec-
tiveness of a combined rehabilitative approach for the 
treatment of FSDs associated with UUI, where electrical 
stimulation is applied together with biofeedback, pelvic 
floor muscle exercises, and vaginal cones [82, 83].
The mode of action of TES involves increasing the 
contraction of the sphincter on the urethra, and the 
strength of the PFMs to hold the pelvic structures [84].
The resulting muscle hypertrophy could also exert 
a  passive mechanical pressure on the urethra, thus 
helping to improve symptoms in SUI. When PFMs are 
stimulated trough TES, the short bust of electricity could 
induce reflexes to induce the contraction of para- and 
peri-urethral muscles and the inhibition of the detru-
sor activity [85]. The inhibitory reflex also improves the 
bladder storage. To benefit from these effects, patients 
with UUI need to have an intact peripheral neuronal 
pathway to the PFMs [81].
For women in whom more conservative treatments 
fail, the next option is SN, the lowest invasive procedure 
that allows the avoidance or postponement of major 
interventions [70]. Tanagho and Schmidt were the first 
to report the use of this procedure in 1988, where the 
implant of an electrode in the S3-S4 sacral foramen al-
lowing to provide ongoing stimuli to the sacral nerves, 
thus improving urinary symptoms [85]. During the pro-
cedure, an electrode is placed percutaneously via the 
S3 foramen, which provides low-amplitude electrical 
stimulation to the S3 nerve root and results in chang-
es to bladder storage function [86, 87]. The mechanism 
of action of SN is not fully understood. The most well- 
accepted hypothesised mechanism is that the effects 
of SN derive from stimulation of the alpha myelinated 
afferent fibres and unmyelinated C fibres in the S3 and 
S4 pelvic and pudendal nerve roots that affect the mic-
turition reflex [87, 88]. Several studies have underlined 
that SN also affects the activity in the brain [70]. The 
resulting effect of central neuromodulation in several 
areas has been demonstrated with both positron emis-
sion tomography (PET) and functional magnetic reso-
nance imaging (fMRI) [89]. 
Efficacy of SN has been demonstrated in literature 
in both short and long term [87]. Improvement in uri-
nary symptoms from SN reported in case series and 
randomized ranges from 64% to 88% [70]. Refractory 
OAB symptoms can be improved by up to 50% with SN, 
as a few RCTs have shown [90-92]. 
Regarding sexual function of women treated with 
SN, the data available in literature seem to highlight 
a  positive effect of SN on sexual function of women 
with pelvic floor disorders, even if actual evidence is 
still insufficient to definitely confirm the effectiveness 
of this procedure for the treatment of FSDs [93, 94]. 
In conclusion, both TES and SN seem to be viable 
treatment options for patients with refractory overac-
tive bladder. However, further studies are needed in or-
der to better understand the effectiveness and limits 
of these therapies and their impact on quality of life, 
sexual function, and psychological well-being. 
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